Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies.

Front Pharmacol · 2021 · PMC8240755 · PMID 34211392

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a marginal trendno p-value reported

The Efficacy and Safety of Low-Dose Rivaroxaban Prior RCT trial (J-ROCKET) showed that low-dose rivaroxaban therapy was related to a marginal trend toward a reduction in stroke/SE (HR: 0.49, 95% CI: 0.24–1.00) and a similar risk in major bleeding (HR: 0.85, 95% CI: 0.50–1.43) vs. warfarin in Japanese patients ( Hori et al., 2012 ).

also in 626 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.